DE602007014400D1 - Behandlung pervasiver entwicklungsstörungen - Google Patents

Behandlung pervasiver entwicklungsstörungen

Info

Publication number
DE602007014400D1
DE602007014400D1 DE602007014400T DE602007014400T DE602007014400D1 DE 602007014400 D1 DE602007014400 D1 DE 602007014400D1 DE 602007014400 T DE602007014400 T DE 602007014400T DE 602007014400 T DE602007014400 T DE 602007014400T DE 602007014400 D1 DE602007014400 D1 DE 602007014400D1
Authority
DE
Germany
Prior art keywords
treatment
protein
source
development disorders
pervasive development
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007014400T
Other languages
German (de)
English (en)
Inventor
Andrew Sean Lynch
Kerry Louisa Hambleton
Stephen Leyland Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shs Int Ltd
SHS International Ltd
Original Assignee
Shs Int Ltd
SHS International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shs Int Ltd, SHS International Ltd filed Critical Shs Int Ltd
Publication of DE602007014400D1 publication Critical patent/DE602007014400D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12Fatty acids or derivatives thereof
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135Bacteria or derivatives thereof, e.g. probiotics
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15Vitamins
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16Inorganic salts, minerals or trace elements
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17Amino acids, peptides or proteins
    • A23L33/175Amino acids
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21Addition of substantially indigestible substances, e.g. dietary fibres
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745Bifidobacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747Lactobacilli, e.g. L. acidophilus or L. brevis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602007014400T 2006-12-14 2007-12-14 Behandlung pervasiver entwicklungsstörungen Active DE602007014400D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0624879.3A GB0624879D0 (en) 2006-12-14 2006-12-14 Treatment of pervasive development disorders
PCT/GB2007/004815 WO2008071991A1 (en) 2006-12-14 2007-12-14 Treatment of pervasive developmental disorders

Publications (1)

Publication Number Publication Date
DE602007014400D1 true DE602007014400D1 (de) 2011-06-16

Family

ID=37712065

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007014400T Active DE602007014400D1 (de) 2006-12-14 2007-12-14 Behandlung pervasiver entwicklungsstörungen

Country Status (16)

Country Link
US (1) US20100055073A1 (https=)
EP (1) EP2091526B1 (https=)
JP (1) JP2010513259A (https=)
AT (1) ATE507827T1 (https=)
AU (1) AU2007331276A1 (https=)
BR (1) BRPI0720230B8 (https=)
CA (1) CA2672738A1 (https=)
DE (1) DE602007014400D1 (https=)
ES (1) ES2365469T3 (https=)
GB (1) GB0624879D0 (https=)
IL (1) IL199340A0 (https=)
MX (1) MX2009006459A (https=)
PL (1) PL2091526T3 (https=)
RU (1) RU2441652C2 (https=)
WO (1) WO2008071991A1 (https=)
ZA (1) ZA200904240B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010137944A1 (en) * 2009-05-27 2010-12-02 N.V. Nutricia Treatment of hypercalcaemia
MX2013003636A (es) * 2013-03-27 2014-09-29 Palsgaard Ind De Mexico S De R L De C V Complemento alimenticio para personas con trisomia 21, transtorno del espectro autista y/o transtorno por deficit de atencion con o sin hiperactividad.
WO2015002527A1 (en) * 2013-07-05 2015-01-08 N.V. Nutricia Amino acid composition for use in the treatment of a pdd
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
US11617731B2 (en) 2017-04-28 2023-04-04 Axcella Health, Inc. Amino acid compositions and their use for the treatment of traumatic brain injury
US11541068B2 (en) 2017-05-24 2023-01-03 Glycom A/S HMO compositions and methods for reducing autism spectrum disorder symptoms
IL296055A (en) 2017-08-14 2022-10-01 Axcella Health Inc Amino acid compositions for the treatment of liver disease
MA52971A (fr) 2018-06-20 2021-04-28 Axcella Health Inc Compositions et procédés pour le traitement de l'infiltration de graisse dans le muscle
WO2022258873A1 (es) * 2021-06-09 2022-12-15 Hospital Sant Joan De Deu Combinación nutracéutica y su uso para el tratamiento de trastornos neurológicos

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4414238A (en) * 1981-12-24 1983-11-08 Cutter Laboratories, Inc. Liquid elemental diet
US6294520B1 (en) * 1989-03-27 2001-09-25 Albert T. Naito Material for passage through the blood-brain barrier
US5326569A (en) * 1992-12-23 1994-07-05 Abbott Laboratories Medical foods for the nutritional support of child/adult metabolic diseases
US5719133A (en) * 1994-09-21 1998-02-17 Novartis Nutrition Ag Adolescent dietary composition
SE510813C2 (sv) * 1997-12-08 1999-06-28 Arla Ekonomisk Foerening Bakteriestam av arten Lactobacillus Paracasei subsp. paracasei, sammansättning därav för användning i livsmedel, samt produkt innehållande stammen
AU2002236527A1 (en) * 2000-11-30 2002-06-11 The Health Research Institute Nutrient supplements and methods for treating autism and for preventing the onset of autism
KR100864267B1 (ko) * 2001-06-14 2008-10-20 엔.브이.오가논 AMPA 수용체의 양성 조절제로서의(피리도/티에노)-[f]-옥사제핀-5-온 유도체
US20040005304A1 (en) * 2002-07-08 2004-01-08 Mak Wood, Inc. Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions

Also Published As

Publication number Publication date
AU2007331276A2 (en) 2011-03-31
RU2441652C2 (ru) 2012-02-10
GB0624879D0 (en) 2007-01-24
ES2365469T3 (es) 2011-10-06
RU2009126763A (ru) 2011-01-20
PL2091526T3 (pl) 2011-10-31
AU2007331276A1 (en) 2008-06-19
US20100055073A1 (en) 2010-03-04
BRPI0720230B1 (pt) 2020-12-15
IL199340A0 (en) 2010-03-28
MX2009006459A (es) 2009-11-23
ATE507827T1 (de) 2011-05-15
EP2091526B1 (en) 2011-05-04
BRPI0720230B8 (pt) 2021-05-25
BRPI0720230A2 (pt) 2013-12-24
JP2010513259A (ja) 2010-04-30
EP2091526A1 (en) 2009-08-26
CA2672738A1 (en) 2008-06-19
ZA200904240B (en) 2010-08-25
WO2008071991A1 (en) 2008-06-19

Similar Documents

Publication Publication Date Title
DE602007014400D1 (de) Behandlung pervasiver entwicklungsstörungen
EA201170508A1 (ru) Производные 1-амино-2-циклобутилэтилбороновой кислоты
MY157661A (en) Bendamustine pharmaceutical compositions
EA201300121A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
NO20083780L (no) Topisk sammensetning omfattende en antibakteriell substans
ES2488407T3 (es) Preparación farmacéutica que contiene lipasa de origen bacteriano
MA32539B1 (fr) Traitement du diabète chez des patients pour lesquels une thérapie par la metformine n'est pas appropriée
EA200801826A1 (ru) Дейтерированные производные катехоламина и лекарственные средства, содержащие указанные соединения
NO20084652L (no) Deazapuriner anvendelige som inhibitorer av januskinaser
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
EA200802054A1 (ru) Ингибиторы фермента
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
ATE530544T1 (de) Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren
TW200728305A (en) Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease
EA201100921A1 (ru) Соединения, фармацевтические композиции и способы их применения при лечении нарушений обмена веществ
EA200971107A1 (ru) Катехоламиновые производные, полезные для лечения болезни паркинсона
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
EA200801580A1 (ru) Новые производные пирониндола и способ их получения
MA35895B1 (fr) Inhibiteurs d'iap
EA201000854A1 (ru) Применение эдта и ее солей для профилактики и лечения дизентерии свиней и усиления эффектов антибиотиков, проявляющихся при этом заболевании
BRPI0517435A (pt) triazóis úteis como inibidores de proteìna cinase
EP2257161A4 (en) AHCY-HYDROLASE INHIBITOR FOR THE TREATMENT OF HYPERHOMOCYSTEINEMIA
NO20076405L (no) Anvendelse av 24-nor-UDCA
TW200639155A (en) Thiazolidinones, their production and use as pharmaceutical agents